BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bay Area's Igenica, Inc. Brings In $14 Million In Additional Series C Funding


1/28/2014 7:36:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Igenica Raises $14 Million in Additional Series C Funding to Advance Product Pipeline and Technology Platform

BURLINGAME, Calif.--(BUSINESS WIRE)-- Igenica, Inc., a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it raised $14 million in a Series C extension financing. All major current investors participated in the round, including The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures.

“This financing reflects the enthusiasm of the investment syndicate for the compelling drug candidates and antibody-drug conjugate technology Igenica is developing,” said David V. Goeddel, Ph.D., chairman of Igenica and managing partner of The Column Group.

“As we strengthen our product focus, these funds will be used to advance IGN523 through early clinical trials aimed at safety and clinical activity assessments in acute myelogeneous leukemia. It also will enable us to continue to discover and develop new therapeutics based on our innovative ADC platform to expand Igenica’s pipeline and to increase strategic flexibility as we execute on our business and clinical development plans,” said Mary Haak-Frendscho, Ph.D., chief executive officer of Igenica.

About Igenica, Inc.

Igenica, Inc. is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. For more information, please visit www.igenica.com.

Contact:
Pure Communications Inc.
Katie Wilson, 910-509-3977
katie@purecommunicationsinc.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES